La Jolla Pharmaceutical Company
Subsidiary focused on development, regulatory approval, commercialization, and medical affairs for therapies in critical care and infectious disease. Activities include late‑stage clinical development, pharmacometrics and bioanalysis, medical education for healthcare professionals, antimicrobial susceptibility testing and post‑marketing safety reporting.
Industries
Nr. of Employees
medium (51-250)
La Jolla Pharmaceutical Company
Waltham, Massachusetts, United States
Products
GIAPREZA (angiotensin II)
Intravenous angiotensin II therapy indicated to increase blood pressure in adults with septic or other distributive shock.
Nuzolvence (zoliflodacin)
Oral, single‑dose antibiotic developed for treatment of uncomplicated urogenital gonorrhea (investigational/approved in select jurisdictions based on development stage).
XERAVA (eravacycline)
Intravenous tetracycline‑class antibacterial indicated for complicated intra‑abdominal infections in adults.
XACDURO (sulbactam; durlobactam)
Intravenous co‑packaged combination of a β‑lactam and β‑lactamase inhibitor developed for treatment of multidrug‑resistant Acinetobacter infections; approved for specified hospital‑acquired and ventilator‑associated pneumonias caused by susceptible isolates.
ZEVTERA (ceftobiprole)
Intravenous advanced‑generation cephalosporin with activity against certain Gram‑positive and Gram‑negative pathogens, including some methicillin‑resistant Staphylococcus aureus isolates.
GIAPREZA (angiotensin II)
Intravenous angiotensin II therapy indicated to increase blood pressure in adults with septic or other distributive shock.
Nuzolvence (zoliflodacin)
Oral, single‑dose antibiotic developed for treatment of uncomplicated urogenital gonorrhea (investigational/approved in select jurisdictions based on development stage).
XERAVA (eravacycline)
Intravenous tetracycline‑class antibacterial indicated for complicated intra‑abdominal infections in adults.
XACDURO (sulbactam; durlobactam)
Intravenous co‑packaged combination of a β‑lactam and β‑lactamase inhibitor developed for treatment of multidrug‑resistant Acinetobacter infections; approved for specified hospital‑acquired and ventilator‑associated pneumonias caused by susceptible isolates.
ZEVTERA (ceftobiprole)
Intravenous advanced‑generation cephalosporin with activity against certain Gram‑positive and Gram‑negative pathogens, including some methicillin‑resistant Staphylococcus aureus isolates.
Services
Provision of medical information support for U.S. clinicians, distribution of full prescribing information and instructions for use, and hosting of educational materials (including video content) for healthcare professionals.
Consideration and administration of investigator‑initiated research (IIR) and independent medical education grants through an application and review process.
Provision of medical information support for U.S. clinicians, distribution of full prescribing information and instructions for use, and hosting of educational materials (including video content) for healthcare professionals.
Consideration and administration of investigator‑initiated research (IIR) and independent medical education grants through an application and review process.
Expertise Areas
- Clinical trial management (Phase 2–3 registrational programs)
- Regulatory affairs for anti‑infective and critical care products
- Antimicrobial drug development and susceptibility testing
- Medical affairs and healthcare professional education
Key Technologies
- Registrational Phase 2–3 clinical trial platforms
- Population pharmacokinetic (PPK) modeling
- Pharmacodynamic (PD) evaluations and model‑based dose optimization
- In vitro susceptibility testing (MIC, broth microdilution)
News & Updates
U.S. FDA approval announced for an intravenous co‑packaged β‑lactam/β‑lactamase inhibitor product for treatment of HABP/VABP caused by susceptible Acinetobacter isolates.
Detailed results from the multicenter Phase 3 ATTACK trial comparing sulbactam‑durlobactam versus colistin for serious Acinetobacter infections were published.
Announcement of completed enrollment for the global Phase 3 registrational trial of an oral antibiotic for uncomplicated gonorrhea conducted in collaboration with a public‑health non‑profit partner.
Announcement of a senior medical appointment to lead Clinical, Regulatory, Safety, and Medical Affairs teams.
Company announced a distribution and licensing agreement for an antimicrobial product in select international markets.
U.S. FDA approval announced for a first‑in‑class, single‑dose oral antibiotic for uncomplicated urogenital gonorrhea.
U.S. FDA approval announced for an intravenous co‑packaged β‑lactam/β‑lactamase inhibitor product for treatment of HABP/VABP caused by susceptible Acinetobacter isolates.
Detailed results from the multicenter Phase 3 ATTACK trial comparing sulbactam‑durlobactam versus colistin for serious Acinetobacter infections were published.
Announcement of completed enrollment for the global Phase 3 registrational trial of an oral antibiotic for uncomplicated gonorrhea conducted in collaboration with a public‑health non‑profit partner.
Announcement of a senior medical appointment to lead Clinical, Regulatory, Safety, and Medical Affairs teams.
Company announced a distribution and licensing agreement for an antimicrobial product in select international markets.
U.S. FDA approval announced for a first‑in‑class, single‑dose oral antibiotic for uncomplicated urogenital gonorrhea.